CERE News and Press, Ceres Inc. From 03/11/24

2024-03-11 19:11:51 ET Summary Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major Depressive Disorder. CAPLYTA's growing acceptan...

2024-03-11 08:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-10 12:23:46 ET Summary AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth....

2024-03-08 15:00:00 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat ETFs...

2024-03-06 07:20:44 ET Summary The FTC is requesting more information on the merger between Cerevel Therapeutics and AbbVie. Concerns may be focused on the Phase 3 treatment Tavapadon for Parkinson's disease. The market expects a 75% chance of the acquisition going through, wh...

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

2024-02-21 13:26:32 ET More on AbbVie AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding AbbVie: Game Changer AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq AbbVie names Robert A. Michael as CEO and Richard A. Gonzalez...

2024-02-18 10:22:04 ET Summary Karuna Therapeutics is developing a novel product, KarXT, to treat psychoses related to Alzheimer's and schizophrenia. The product targets muscarinic receptors in an agonist/antagonist combination. Some shareholders are suing to prevent the acqui...

2024-02-16 17:56:00 ET More on AbbVie, Cerevel Therapeutics, etc. AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding AbbVie: Game Changer AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq Dividend Roundup: Target, Meta Pl...